TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) – Pipeline Review, H2 2016’, provides in depth analysis on TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted pipeline therapeutics.

The report provides comprehensive information on the TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30)

The report reviews TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics and enlists all their major and minor projects

The report assesses TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Eli Lilly and Company

Oncodesign SA

Oncomatryx Biopharma, S.L.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC

2.7.11.30) Overview 6

Therapeutics Development 7

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC

2.7.11.30) - Products under Development by Stage of Development 7

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC

2.7.11.30) - Products under Development by Therapy Area 8

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC

2.7.11.30) - Products under Development by Indication 9

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC

2.7.11.30) - Pipeline Products Glance 10

Early Stage Products 10

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC

2.7.11.30) - Products under Development by Companies 11

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC

2.7.11.30) - Therapeutics Assessment 13

Assessment by Monotherapy/Combination Products 13

Assessment by Mechanism of Action 14

Assessment by Route of Administration 15

Assessment by Molecule Type 17

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC

2.7.11.30) - Companies Involved in Therapeutics Development 19

Eli Lilly and Company 19

Oncodesign SA 20

Oncomatryx Biopharma, S.L. 21

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC

2.7.11.30) - Drug Profiles 22

Antibody to Antagonise TGF Beta Receptor Type 2 for Oncology - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

ITD-1 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

OMTX-001 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

Small Molecules to Antagonize Transforming Growth Factor Beta Receptor II for Oncology - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC

2.7.11.30) - Dormant Projects 28

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC

2.7.11.30) - Discontinued Products 29

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC

2.7.11.30) - Featured News & Press Releases 30

Nov 14, 2012: Small molecule makes heart cells out of stem cells 30

Appendix 31

Methodology 31

Coverage 31

Secondary Research 31

Primary Research 31

Expert Panel Validation 31

Contact Us 31

Disclaimer 32

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Products under Development by Companies, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 13

Number of Products by Stage and Mechanism of Action, H2 2016 14

Number of Products by Stage and Route of Administration, H2 2016 16

Number of Products by Stage and Molecule Type, H2 2016 18

Pipeline by Eli Lilly and Company, H2 2016 19

Pipeline by Oncodesign SA, H2 2016 20

Pipeline by Oncomatryx Biopharma, S.L., H2 2016 21

Dormant Projects, H2 2016 28

Discontinued Products, H2 2016 29

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy/Combination Products, H2 2016 13

Number of Products by Stage and Mechanism of Actions, H2 2016 14

Number of Products by Routes of Administration, H2 2016 15

Number of Products by Stage and Routes of Administration, H2 2016 15

Number of Products by Molecule Types, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 17

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared